{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:12:04Z","timestamp":1791231124281,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,15]]},"DOI":"10.1093\/cid\/cit296","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T19:20:11Z","timestamp":1374693611000},"page":"S39-S45","source":"Crossref","is-referenced-by-count":273,"title":["Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy"],"prefix":"10.1093","volume":"57","author":[{"given":"Natasha K.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"key\n\t\t\t\t20171013234947_CIT296C1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infec Dis"},{"key":"key\n\t\t\t\t20171013234947_CIT296C2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"The Lancet"},{"key":"key\n\t\t\t\t20171013234947_CIT296C3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0962280208094691","article-title":"An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales","volume":"18","author":"De Angelis","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"key\n\t\t\t\t20171013234947_CIT296C4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"The Lancet"},{"key":"key\n\t\t\t\t20171013234947_CIT296C5","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","article-title":"The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence","volume":"106","author":"Turner","year":"2011","journal-title":"Addiction"},{"key":"key\n\t\t\t\t20171013234947_CIT296C6","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1360-0443.2012.03932.x","article-title":"Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings","volume":"107","author":"Vickerman","year":"2012","journal-title":"Addiction"},{"key":"key\n\t\t\t\t20171013234947_CIT296C7","doi-asserted-by":"crossref","first-page":"e5945","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: a systematic review and meta-analysis","volume":"345","author":"Macarthur","year":"2012","journal-title":"British Medical Journal"},{"key":"key\n\t\t\t\t20171013234947_CIT296C8","doi-asserted-by":"crossref","first-page":"c5475","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20171013234947_CIT296C9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.2011.03637.x","article-title":"Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study","volume":"107","author":"Bukten","year":"2012","journal-title":"Addiction"},{"key":"key\n\t\t\t\t20171013234947_CIT296C10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility","volume":"54","author":"Martin","year":"2011","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171013234947_CIT296C11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtbi.2010.12.041","article-title":"Mathematical modelling of hepatitis C treatment for injecting drug users","volume":"274","author":"Martin","year":"2011","journal-title":"J Theor Biol"},{"key":"key\n\t\t\t\t20171013234947_CIT296C12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2010.08.001","article-title":"Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere","volume":"113","author":"Vickerman","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"key\n\t\t\t\t20171013234947_CIT296C13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.5694\/mja11.10981","article-title":"Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia","volume":"196","author":"Hellard","year":"2012","journal-title":"Med J Aust"},{"key":"key\n\t\t\t\t20171013234947_CIT296C14","doi-asserted-by":"crossref","DOI":"10.1002\/hep.26431","article-title":"HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171013234947_CIT296C15","article-title":"Assessing the cost-effectiveness of interventions aimed at promoting and offering hepatitis C testing in injecting drug users: an economic modelling report","author":"Martin"},{"key":"key\n\t\t\t\t20171013234947_CIT296C16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171013234947_CIT296C17","article-title":"Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: A systematic review and meta-analysis","author":"Aspinall"},{"key":"key\n\t\t\t\t20171013234947_CIT296C18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013234947_CIT296C19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013234947_CIT296C20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.5694\/mja11.11531","article-title":"The changing therapeutic landscape for hepatitis C","volume":"196","author":"Dore","year":"2012","journal-title":"Med J Aust"},{"key":"key\n\t\t\t\t20171013234947_CIT296C21","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(06)68804-1","article-title":"Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis","volume":"367","author":"Nordt","year":"2006","journal-title":"The Lancet"},{"key":"key\n\t\t\t\t20171013234947_CIT296C22","volume-title":"European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and Drug Addiction, Prevention and control of infectious diseases among people who inject drugs","year":"2011"},{"key":"key\n\t\t\t\t20171013234947_CIT296C23","doi-asserted-by":"crossref","first-page":"e34548","DOI":"10.1371\/journal.pone.0034548","article-title":"Treatment of hepatitis C as prevention: A modeling case study in Vietnam","volume":"7","author":"Durier","year":"2012","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t20171013234947_CIT296C24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic Hepatitis CA cost-effectiveness analysis","volume":"156","author":"Liu","year":"2012","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171013234947_CIT296C25","article-title":"A systematic review of the cost-effectiveness of harm reduction for IDUs \u2013 how good is the evidence?","author":"Guinness","year":"2013"},{"key":"key\n\t\t\t\t20171013234947_CIT296C26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0962280208094704","article-title":"Estimating the prevalence of ex-injecting drug use in the population","volume":"18","author":"Sweeting","year":"2009","journal-title":"Stats Meth Med Res"},{"key":"key\n\t\t\t\t20171013234947_CIT296C27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/pubmed\/fdp067","article-title":"Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action","volume":"31","author":"Hickman","year":"2009","journal-title":"J Public Health"},{"key":"key\n\t\t\t\t20171013234947_CIT296C28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systemic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2010","journal-title":"Addiction"},{"key":"key\n\t\t\t\t20171013234947_CIT296C29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171013234947_CIT296C30","article-title":"NICE, Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C","year":"2006"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/57\/suppl_2\/S39\/20911840\/cit296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T23:49:52Z","timestamp":1507938592000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/57\/suppl_2\/S39\/396524\/Combination-Interventions-to-Prevent-HCV"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":30,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2013,8,15]]},"published-print":{"date-parts":[[2013,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit296","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,8,15]]},"published":{"date-parts":[[2013,8,15]]}}}